- In late June 2026, Waters Corporation (NYSE: WAT) was removed from several Russell indices, including the Russell 1000, Russell 3000, and Russell Midcap Growth benchmarks, following the latest index reconstitution.
- These index deletions can matter because they often trigger forced trading by index-linked funds, potentially altering Waters’ institutional ownership mix and liquidity profile.
- Next, we’ll examine how Waters’ removal from multiple Russell indices may influence its previously outlined investment narrative and risk profile.
Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.
Waters Investment Narrative Recap
To own Waters today, you need to believe in its ability to execute on the BD Biosciences and Diagnostic Solutions acquisition while managing weaker demand in academic and pharma discovery markets. The recent removal from multiple Russell indices may affect short term trading and liquidity, but it does not directly change the core catalyst around integration progress or the key risk that synergy targets and earnings expectations could prove difficult to achieve.
The most relevant recent announcement is Waters’ Q1 2026 update and full year guidance, which sets expectations for US$6,405 million to US$6,455 million in revenue despite a one off driven net loss. Against the backdrop of index deletions, upcoming Q2 2026 results now take on added importance as a checkpoint on whether integration, margin initiatives and new product launches are tracking close to those guidance ranges.
Yet investors should also be aware that if integration synergies or funding trends in key end markets disappoint, the impact on Waters’ earnings power could be far more...
Read the full narrative on Waters (it's free!)
Waters' narrative projects $7.7 billion revenue and $1.3 billion earnings by 2029. This requires 27.0% yearly revenue growth and an earnings increase of about $850 million from $449.6 million today.
Uncover how Waters' forecasts yield a $401.78 fair value, a 7% upside to its current price.
Exploring Other Perspectives
Some of the most optimistic analysts were modeling Waters to reach about US$8.4 billion in revenue and US$1.4 billion in earnings by 2029, which is a far more upbeat story than concerns about concentration in chromatography and mass spectrometry suggest, and the recent Russell index removals may lead you to reassess which version of the future feels more realistic.
Explore 3 other fair value estimates on Waters - why the stock might be worth just $401.78!
Decide For Yourself
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your Waters research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
- Our free Waters research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Waters' overall financial health at a glance.
Ready For A Different Approach?
Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:
- The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 16 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
- AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
- Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com